The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, Patrick Marcellin, Daniel Sereni, Hartwig Klinker, Christophe Moreno, Jean‐Pierre Zarski, Yves Horsmans, Hongmei Mo, Sarah Arterburn, Steven Knox, David Oldach, John G. McHutchison, Michael P. Manns, Graham R. Foster – 17 October 2011 – Tegobuvir (GS‐9190), a non‐nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS‐9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1.

Outcome of post–liver transplant ischemic and nonischemic biliary stenoses treated with percutaneous interventions: The bologna experience

Emanuela Giampalma, Matteo Renzulli, Cristina Mosconi, Giorgio Ercolani, Antonio Daniele Pinna, Rita Golfieri – 17 October 2011 – In liver transplantation (LT), biliary strictures (BSs) are among the most common complications. The aim of this study was to evaluate the efficacy of percutaneous treatments in the management of post‐LT BSs. Between 1999 and 2007, 48 patients underwent percutaneous treatments for posttransplant BSs.

Liver transplantation in human immunodeficiency virus–infected patients: Procoagulant, but is antithrombotic prophylaxis required?

P. Thomas Cherian, Wesal Alrabih, Abdel Douiri, Alberto Quaglia, Michael A. Heneghan, John O'Grady, Mohamed Rela, Nigel D. Heaton – 17 October 2011 – Liver transplantation (LT) for human immunodeficiency virus (HIV)–positive recipients with end‐stage liver disease has become an accepted practice. However, because these patients are increasingly being recognized as prothrombotic, we reviewed their posttransplant thrombotic complications.

Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation

Parsia A. Vagefi, Nancy L. Ascher, Chris E. Freise, Jennifer L. Dodge, John P. Roberts – 17 October 2011 – The demographics of patients in the United States who undergo living donor liver transplantation (LDLT) versus patients who undergo deceased donor liver transplantation (DDLT) are interesting with respect to the demographics of the donor service areas (DSAs). We examined adult recipients of primary, non–status 1 liver‐only transplants from 2003 to 2009. The likelihood of undergoing LDLT was compared to the likelihood of undergoing DDLT by multivariate logistic regression.

Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation

Benjamin H. Friedman, Joshua H. Wolf, Liqing Wang, Mary E. Putt, Abraham Shaked, Jason D. Christie, Wayne W. Hancock, Kim M. Olthoff – 17 October 2011 – Early allograft dysfunction (EAD) occurring in the first week post‐liver transplantation is associated with increased graft failure and mortality and is believed to be largely due to ischemia/reperfusion injury.

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

Masanobu Tsuda, Yuki Moritoki, Zhe‐Xiong Lian, Weici Zhang, Katsunori Yoshida, Kanji Wakabayashi, Guo‐Xiang Yang, Toshio Nakatani, John Vierling, Keith Lindor, M. Eric Gershwin, Christopher L. Bowlus – 17 October 2011 – The aim of this study was to determine the safety and potential efficacy of B‐cell depletion with the anti‐CD20 monoclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA).

Subscribe to